Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRIGrowth Rate was -103.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 4 years, Duality Biotherapeutics's highest 3-Year average EPS without NRI Growth Rate was -103.80% per year. The lowest was -103.80% per year. And the median was -103.80% per year.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Duality Biotherapeutics EPS (Diluted) Related Terms
Duality Biotherapeutics EPS (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duality Biotherapeutics EPS (Diluted) Chart
Duality Biotherapeutics Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
EPS (Diluted)
-5.41
-4.75
-13.69
-43.19
Duality Biotherapeutics Semi-Annual Data
Jun25
Dec25
Jun26
EPS (Diluted)
-53.42
-6.38
-11.59
HKSE:09606 vs VRTX, REGN, MRNA: EPS (Diluted) Comparison
For the Biotechnology subindustry, Duality Biotherapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duality Biotherapeutics PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Duality Biotherapeutics's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Duality Biotherapeutics's Diluted EPS for the fiscal year that ended in Dec. 2025 is calculated as
Duality Biotherapeutics (HKSE:09606) has a EPS (Diluted) of HK$ as of Jun. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Duality Biotherapeutics and its competitors.
Is Duality Biotherapeutics' EPS (Diluted) too high?
Duality Biotherapeutics' current EPS (Diluted) is HK$. Overall, Duality Biotherapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' EPS (Diluted) compare to VRTX and REGN?
Duality Biotherapeutics' EPS (Diluted) of HK$ can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Biotechnology company?
A good EPS (Diluted) depends on the Biotechnology industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current EPS (Diluted) is HK$. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (HKSE:09606) has a current EPS (Diluted) of HK$. The current EPS (Diluted) is HK$. Duality Biotherapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Duality Biotherapeutics (HKSE:09606), the current EPS (Diluted) is HK$ as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
9GF Score
Get the complete analysis for HKSE:09606
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09606 has been successfully added to your 
